p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy

(2016) Evguenia M Alexandrova et al.   CELL DEATH AND DIFFERENTIATION

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

(2016) Alejandro Parrales et al.   NATURE CELL BIOLOGY

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

(2015) E. M. Alexandrova et al.   NATURE

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

(2014) Susann Weissmueller et al.   CELL

The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele

(2014) Y Shetzer et al.   CELL DEATH AND DIFFERENTIATION

TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

(2014) L. Silwal-Pandit et al.   CLINICAL CANCER RESEARCH

Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity

(2014) J Xu et al.   Cell Death & Disease

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

(2013) W Hanel et al.   CELL DEATH AND DIFFERENTIATION

Effects ofTP53mutational status on gene expression patterns across 10 human cancer types

(2013) Neha Parikh et al.   JOURNAL OF PATHOLOGY

Multiple Stress Signals Activate Mutant p53 In Vivo

(2011) Y.-A. Suh et al.   CANCER RESEARCH

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

(2011) Anna Yemelyanova et al.   MODERN PATHOLOGY

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma

(2010) Brendan Doyle et al.   JOURNAL OF PATHOLOGY

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

(2009) J. P. Morton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT